(MEDP) Medpace Holdings - Ratings and Ratios
Clinical Trials, Lab Testing, Regulatory Consulting, Data Management
MEDP EPS (Earnings per Share)
MEDP Revenue
Description: MEDP Medpace Holdings
Medpace Holdings, Inc. is a leading provider of clinical research-based services for the pharmaceutical, biotechnology, and medical device industries, operating globally across North America, Europe, and Asia. The companys comprehensive suite of services supports the clinical development process from Phase I to Phase IV across various therapeutic areas.
Key aspects of Medpaces service offerings include clinical development services, development plan design, project management, regulatory affairs, clinical monitoring, data management and analysis, and pharmacovigilance. Additionally, they provide bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials, making them a one-stop-shop for clients.
From a financial perspective, Medpace has demonstrated strong performance, with a Return on Equity (RoE) of 54.36%, indicating efficient use of shareholder capital. To further analyze the companys performance, other key performance indicators (KPIs) such as Revenue Growth Rate, Operating Margin, and Debt-to-Equity Ratio could be examined. For instance, a high Revenue Growth Rate would indicate Medpaces ability to expand its client base and increase its market share. An Operating Margin analysis would provide insights into the companys ability to manage costs and maintain profitability. A low Debt-to-Equity Ratio would suggest that Medpace has a healthy balance sheet and is not over-leveraged.
To evaluate the stocks potential, its essential to consider its valuation multiples. With a Price-to-Earnings (P/E) ratio of 23.81 and a Forward P/E of 25.38, Medpaces stock appears to be reasonably valued compared to its earnings. However, a more comprehensive analysis would involve comparing these multiples to industry averages and examining the companys historical valuation trends.
MEDP Stock Overview
| Market Cap in USD | 13,681m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2016-08-11 |
MEDP Stock Ratings
| Growth Rating | 66.4% |
| Fundamental | 85.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 16.3% |
| Analyst Rating | 3.33 of 5 |
MEDP Dividends
Currently no dividends paidMEDP Growth Ratios
| Growth Correlation 3m | 92.9% |
| Growth Correlation 12m | 1.3% |
| Growth Correlation 5y | 87.5% |
| CAGR 5y | 48.54% |
| CAGR/Max DD 3y | 1.23 |
| CAGR/Mean DD 3y | 5.41 |
| Sharpe Ratio 12m | 0.90 |
| Alpha | 0.19 |
| Beta | 0.060 |
| Volatility | 41.12% |
| Current Volume | 267.8k |
| Average Volume 20d | 325.3k |
| Stop Loss | 486.3 (-3.1%) |
| Signal | 1.31 |
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (418.3m TTM) > 0 and > 6% of Revenue (6% = 133.9m TTM) |
| FCFTA 0.37 (>2.0%) and ΔFCFTA 10.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -31.35% (prev -5.94%; Δ -25.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.39 (>3.0%) and CFO 614.1m > Net Income 418.3m (YES >=105%, WARN >=100%) |
| Net Debt (78.6m) to EBITDA (490.7m) ratio: 0.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (30.2m) change vs 12m ago -5.99% (target <= -2.0% for YES) |
| Gross Margin 31.62% (prev 28.52%; Δ 3.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 127.8% (prev 105.7%; Δ 22.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 30.87 (EBITDA TTM 490.7m / Interest Expense TTM 15.4m) >= 6 (WARN >= 3) |
Altman Z'' -3.08
| (A) -0.45 = (Total Current Assets 520.8m - Total Current Liabilities 1.22b) / Total Assets 1.57b |
| (B) -0.45 = Retained Earnings (Balance) -703.2m / Total Assets 1.57b |
| (C) 0.27 = EBIT TTM 475.7m / Avg Total Assets 1.75b |
| (D) -0.51 = Book Value of Equity -708.6m / Total Liabilities 1.40b |
| Total Rating: -3.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.05
| 1. Piotroski 9.0pt = 4.0 |
| 2. FCF Yield 3.86% = 1.93 |
| 3. FCF Margin 25.98% = 6.49 |
| 4. Debt/Equity 8.12 = -2.50 |
| 5. Debt/Ebitda 2.85 = -1.55 |
| 6. ROIC - WACC (= 59.68)% = 12.50 |
| 7. RoE 67.66% = 2.50 |
| 8. Rev. Trend 96.58% = 7.24 |
| 9. EPS Trend 88.74% = 4.44 |
What is the price of MEDP shares?
Over the past week, the price has changed by +0.87%, over one month by +8.43%, over three months by +65.83% and over the past year by +38.93%.
Is Medpace Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MEDP is around 610.62 USD . This means that MEDP is currently undervalued and has a potential upside of +21.65% (Margin of Safety).
Is MEDP a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MEDP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 422.3 | -15.9% |
| Analysts Target Price | 422.3 | -15.9% |
| ValueRay Target Price | 663.5 | 32.2% |
Last update: 2025-09-08 10:00
MEDP Fundamental Data Overview
CCE Cash And Equivalents = 46.3m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 36.2336
P/E Forward = 32.8947
P/S = 6.1299
P/B = 79.3772
P/EG = 3.7578
Beta = 1.445
Revenue TTM = 2.23b USD
EBIT TTM = 475.7m USD
EBITDA TTM = 490.7m USD
Long Term Debt = 178.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.22b USD (from totalCurrentLiabilities, last quarter)
Debt = 1.40b USD (Calculated: Short Term 1.22b + Long Term 178.9m)
Net Debt = 78.6m USD (from netDebt column, last quarter)
Enterprise Value = 15.03b USD (13.68b + Debt 1.40b - CCE 46.3m)
Interest Coverage Ratio = 30.87 (Ebit TTM 475.7m / Interest Expense TTM 15.4m)
FCF Yield = 3.86% (FCF TTM 579.8m / Enterprise Value 15.03b)
FCF Margin = 25.98% (FCF TTM 579.8m / Revenue TTM 2.23b)
Net Margin = 18.74% (Net Income TTM 418.3m / Revenue TTM 2.23b)
Gross Margin = 31.62% ((Revenue TTM 2.23b - Cost of Revenue TTM 1.53b) / Revenue TTM)
Tobins Q-Ratio = -21.22 (set to none) (Enterprise Value 15.03b / Book Value Of Equity -708.6m)
Interest Expense / Debt = 0.56% (Interest Expense 7.88m / Debt 1.40b)
Taxrate = 15.03% (71.5m / 475.9m)
NOPAT = 404.2m (EBIT 475.7m * (1 - 15.03%))
Current Ratio = 0.43 (Total Current Assets 520.8m / Total Current Liabilities 1.22b)
Debt / Equity = 8.12 (Debt 1.40b / last Quarter total Stockholder Equity 172.4m)
Debt / EBITDA = 2.85 (Net Debt 78.6m / EBITDA 490.7m)
Debt / FCF = 2.41 (Debt 1.40b / FCF TTM 579.8m)
Total Stockholder Equity = 618.2m (last 4 quarters mean)
RoA = 26.61% (Net Income 418.3m, Total Assets 1.57b )
RoE = 67.66% (Net Income TTM 418.3m / Total Stockholder Equity 618.2m)
RoCE = 59.68% (Ebit 475.7m / (Equity 618.2m + L.T.Debt 178.9m))
RoIC = 65.38% (NOPAT 404.2m / Invested Capital 618.2m)
WACC = 5.71% (E(13.68b)/V(15.08b) * Re(6.24%)) + (D(1.40b)/V(15.08b) * Rd(0.56%) * (1-Tc(0.15)))
Shares Correlation 3-Years: -39.39 | Cagr: -0.61%
Discount Rate = 6.24% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈549.0m ; Y1≈677.3m ; Y5≈1.16b
Fair Price DCF = 699.6 (DCF Value 19.65b / Shares Outstanding 28.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 88.74 | EPS CAGR: 16.27% | SUE: 0.45 | # QB: 0
Revenue Correlation: 96.58 | Revenue CAGR: 17.88% | SUE: 4.0 | # QB: 2
Additional Sources for MEDP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle